Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00143871 | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00286845 | Use of the MiCK Assay for Apoptosis in AML | completed | — | 50 | Pierian BiosciencesINDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT01517581 | Brown Fat Activity and White Fat Accumulation | completed | — | 32 | Children's Hospital Los AngelesOTHER | 1 | Jan 25, 2012 | clinicaltrials |
| NCT00042250 | IUdR/BUdR Cell Cycle Labelling | completed | N/A | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT00423709 | Allogeneic Blood Stem Cell Transplantation | completed | N/A | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 23, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | completed | Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 19, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma(VERTICAL) | completed | Phase 2 | 73 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00723346 | Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia(GRASPALL) | completed | Phase 1 / Phase 2 | 25 | ERYtech PharmaINDUSTRY | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00766311 | Aerobic and Strengthening Exercise for Acute Leukemia(XRCISL) | completed | N/A | 20 | St. Jude Children's Research HospitalOTHER | 1 | Jan 9, 2012 | clinicaltrials |
| NCT00677859 | Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | completed | Phase 1 | 36 | Healios K.K.INDUSTRY | 2 | Jan 5, 2012 | clinicaltrials |
| NCT00505232 | Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)(LCM-04-02) | completed | Phase 2 | 30 | CABYCINDUSTRY | 1 | Jan 2, 2012 | clinicaltrials |
| NCT00006379 | Non-Ablative Allo HSCT For Hematologic Malignancies or SAA | completed | Phase 2 | 58 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00935844 | Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 20 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00525876 | Non-Myeloablative Allogeneic Stem Cell Transplantation | completed | N/A | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00760370 | Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer | completed | Phase 2 | 60 | Vejle HospitalOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00388999 | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant | completed | Phase 1 | 46 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00436904 | Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | completed | Phase 2 | 30 | Mayo ClinicOTHER | 1 | Dec 1, 2011 | clinicaltrials |
| NCT00002456 | Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | completed | Phase 3 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00002553 | Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00003887 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00005854 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00006241 | Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00027547 | Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 2 | Nov 30, 2011 | clinicaltrials |
| NCT00089050 | Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00093366 | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00244829 | Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT01374139 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | completed | Phase 1 | 88 | PfizerINDUSTRY | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00003874 | Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 29, 2011 | clinicaltrials |
| NCT01266668 | The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) | completed | — | 100 | Chonbuk National University HospitalOTHER | 1 | Nov 29, 2011 | clinicaltrials |
| NCT01479387 | Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan(ZEVALIN-SDUI) | completed | — | 72 | BayerINDUSTRY | 1 | Nov 24, 2011 | clinicaltrials |
| NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | completed | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT01478269 | Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen(ProDLBCL) | completed | — | 1,927 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Nov 23, 2011 | clinicaltrials |
| NCT00144092 | HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma | completed | Phase 2 | 60 | Alberta Health servicesOTHER | 1 | Nov 21, 2011 | clinicaltrials |
| NCT00110058 | Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 17, 2011 | clinicaltrials |
| NCT01470924 | Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007 | completed | — | 76 | Region Örebro CountyOTHER | 1 | Nov 11, 2011 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00038844 | Safety and Efficacy of Campath in Nonmyeloablative Transplantation | completed | N/A | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
Data updated 24 days agoSource updated Feb 1, 2012source: clinicaltrials